Drug Profile
SH 229
Alternative Names: Holybuvir; SH-229Latest Information Update: 22 Apr 2022
Price :
$50
*
At a glance
- Originator Nanjing Sanhome Pharmaceutical
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Hepatitis C
Most Recent Events
- 22 Apr 2022 SH 229 is still in phase II/III trials for chronic Hepatitis C (Combination therapy, Treatment-naive, Treatment-resistant) in China (PO) (NCT04070235)
- 20 Aug 2021 Efficacy and adverse events data of a phase III trial in Hepatitis C presented at The International Liver Congress 2021 (ILC-2021)
- 20 Aug 2021 Nanjing Sanhome Pharmaceutical completes a phase II/III trial in chronic Hepatitis C (Combination therapy, Treatment-naive, Treatment-resistant) in China (PO) (NCT04070235)